EETs/sEH in diabetes and obesity-induced cardiovascular diseases

Hui Huang, Jing Weng, Mong-Heng Wang

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Despite the optimization of blood glucose control and the therapeutic management of risk factors, obesity- and diabetes-induced cardiovascular diseases are still major health problems in the United States. Arachidonic acid (AA), an endogenous 20-carbon polyunsaturated fatty acid, is metabolized by cytochrome P450 (CYP) epoxygenases into epoxyeicosatrienoic acids (EETs), which are important lipid mediators with many beneficial effects in type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and obesity- and diabetes-induced cardiovascular diseases. EETs can be further metabolized to less active dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH). It has been demonstrated that the use of sEH blockers, which prevent EET degradation, is a promising pharmacological approach to promoting insulin secretion, preventing endothelial dysfunction, decreasing blood pressure, and protecting against target organ damage in obesity and metabolic diseases. This review will focus on biochemistry of CYP monooxygenase system as well as the pharmacology and physiological significance of EETs and sEH. We will also discuss the role of EETs/sEH in T1DM, T2DM, and obesity- and diabetes-induced cardiovascular diseases.

Original languageEnglish (US)
Pages (from-to)80-89
Number of pages10
JournalProstaglandins and Other Lipid Mediators
Volume125
DOIs
StatePublished - Sep 1 2016

Fingerprint

Epoxide Hydrolases
Medical problems
Cardiovascular Diseases
Obesity
Acids
Type 1 Diabetes Mellitus
Cytochrome P-450 Enzyme System
Type 2 Diabetes Mellitus
Pharmacology
Metabolic Diseases
Mixed Function Oxygenases
Unsaturated Fatty Acids
Arachidonic Acid
Biochemistry
Blood Glucose
Blood pressure
Carbon
Insulin
Blood Pressure
Lipids

Keywords

  • Cytochrome P450
  • Diabetes
  • Eicosanoids
  • Obesity
  • Soluble epoxide hydrolase

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Pharmacology
  • Cell Biology

Cite this

EETs/sEH in diabetes and obesity-induced cardiovascular diseases. / Huang, Hui; Weng, Jing; Wang, Mong-Heng.

In: Prostaglandins and Other Lipid Mediators, Vol. 125, 01.09.2016, p. 80-89.

Research output: Contribution to journalReview article

@article{307ba3f6028241d9b9542d165f61e791,
title = "EETs/sEH in diabetes and obesity-induced cardiovascular diseases",
abstract = "Despite the optimization of blood glucose control and the therapeutic management of risk factors, obesity- and diabetes-induced cardiovascular diseases are still major health problems in the United States. Arachidonic acid (AA), an endogenous 20-carbon polyunsaturated fatty acid, is metabolized by cytochrome P450 (CYP) epoxygenases into epoxyeicosatrienoic acids (EETs), which are important lipid mediators with many beneficial effects in type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and obesity- and diabetes-induced cardiovascular diseases. EETs can be further metabolized to less active dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH). It has been demonstrated that the use of sEH blockers, which prevent EET degradation, is a promising pharmacological approach to promoting insulin secretion, preventing endothelial dysfunction, decreasing blood pressure, and protecting against target organ damage in obesity and metabolic diseases. This review will focus on biochemistry of CYP monooxygenase system as well as the pharmacology and physiological significance of EETs and sEH. We will also discuss the role of EETs/sEH in T1DM, T2DM, and obesity- and diabetes-induced cardiovascular diseases.",
keywords = "Cytochrome P450, Diabetes, Eicosanoids, Obesity, Soluble epoxide hydrolase",
author = "Hui Huang and Jing Weng and Mong-Heng Wang",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.prostaglandins.2016.05.004",
language = "English (US)",
volume = "125",
pages = "80--89",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - EETs/sEH in diabetes and obesity-induced cardiovascular diseases

AU - Huang, Hui

AU - Weng, Jing

AU - Wang, Mong-Heng

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Despite the optimization of blood glucose control and the therapeutic management of risk factors, obesity- and diabetes-induced cardiovascular diseases are still major health problems in the United States. Arachidonic acid (AA), an endogenous 20-carbon polyunsaturated fatty acid, is metabolized by cytochrome P450 (CYP) epoxygenases into epoxyeicosatrienoic acids (EETs), which are important lipid mediators with many beneficial effects in type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and obesity- and diabetes-induced cardiovascular diseases. EETs can be further metabolized to less active dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH). It has been demonstrated that the use of sEH blockers, which prevent EET degradation, is a promising pharmacological approach to promoting insulin secretion, preventing endothelial dysfunction, decreasing blood pressure, and protecting against target organ damage in obesity and metabolic diseases. This review will focus on biochemistry of CYP monooxygenase system as well as the pharmacology and physiological significance of EETs and sEH. We will also discuss the role of EETs/sEH in T1DM, T2DM, and obesity- and diabetes-induced cardiovascular diseases.

AB - Despite the optimization of blood glucose control and the therapeutic management of risk factors, obesity- and diabetes-induced cardiovascular diseases are still major health problems in the United States. Arachidonic acid (AA), an endogenous 20-carbon polyunsaturated fatty acid, is metabolized by cytochrome P450 (CYP) epoxygenases into epoxyeicosatrienoic acids (EETs), which are important lipid mediators with many beneficial effects in type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and obesity- and diabetes-induced cardiovascular diseases. EETs can be further metabolized to less active dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH). It has been demonstrated that the use of sEH blockers, which prevent EET degradation, is a promising pharmacological approach to promoting insulin secretion, preventing endothelial dysfunction, decreasing blood pressure, and protecting against target organ damage in obesity and metabolic diseases. This review will focus on biochemistry of CYP monooxygenase system as well as the pharmacology and physiological significance of EETs and sEH. We will also discuss the role of EETs/sEH in T1DM, T2DM, and obesity- and diabetes-induced cardiovascular diseases.

KW - Cytochrome P450

KW - Diabetes

KW - Eicosanoids

KW - Obesity

KW - Soluble epoxide hydrolase

UR - http://www.scopus.com/inward/record.url?scp=84970028145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970028145&partnerID=8YFLogxK

U2 - 10.1016/j.prostaglandins.2016.05.004

DO - 10.1016/j.prostaglandins.2016.05.004

M3 - Review article

VL - 125

SP - 80

EP - 89

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

ER -